Dengue

WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue burden and transmission intensity

Gary Dubin, President, Global Vaccine Business Unit, Takeda, and Dion Warren, Head of Multi-Country Organization, India &…

The partnership will build upon existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany and…

This research lays the foundation for innovative mosquito control methods, potentially reducing disease transmission

This can provide a future avenue for the development of broad-spectrum antiviral drugs that might reduce the clinical burden…

It also recognised strong public health benefit to be gained by introduction of Dengvaxia, dengue vaccine

The project was jointly undertaken by DBT, ICGEB and Ranbaxy Research Laboratory and employed Ayurveda in devising the drug In a…

The vaccine administered in three doses over a one-year period will help prevent the disease caused by all four dengue types in…

Initiates partnership proposal for research on human infectious diseases with Infect-ERA NET A future strategy for Indo – US…

Bengaluru-based Micro Labs recently launched Caripill which helps to increase the platelet count in patients suffering from…